Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Uncommon Pathological Types of Lung Cancer”

11 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 11 results

Not applicableStudy completedNCT05023837
What this trial is testing

Efficacy and Safety of Immunotherapy in Non-small Cell Lung Cancer With Uncommon Histological Type

Who this might be right for
Uncommon Pathological Types of Lung Cancer
Hunan Province Tumor Hospital 40
Not applicableLooking for participantsNCT03740503
What this trial is testing

Genomic Investigation of Unusual Responders

Who this might be right for
CancerBreast CancerNon-small Cell Lung Cancer+8 more
University Health Network, Toronto 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT02834013
What this trial is testing

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Who this might be right for
Acinar Cell CarcinomaAdenoid Cystic CarcinomaAdrenal Cortical Carcinoma+91 more
National Cancer Institute (NCI) 818
Not applicableLooking for participantsNCT06539169
What this trial is testing

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

Who this might be right for
Alpha-ThalassemiaBeta-ThalassemiaAmyloidosis+14 more
xCures 1,000
Testing effectiveness (Phase 2)Study completedNCT03602079
What this trial is testing

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Who this might be right for
HER2-positive Breast CancerHER2 Gene MutationHER-2 Gene Amplification+41 more
Klus Pharma Inc. 49
Not applicableEnrolling By InvitationNCT03655223
What this trial is testing

Early Check: Expanded Screening in Newborns

Who this might be right for
Spinal Muscular AtrophyFragile X SyndromeFragile X - Premutation+182 more
RTI International 30,000
Large-scale testing (Phase 3)Study completedNCT00790400
What this trial is testing

Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)

Who this might be right for
Tuberous Sclerosis Complex (TSC)Lymphangioleiomyomatosis (LAM)
Novartis Pharmaceuticals 118
Not applicableLooking for participantsNCT06573723
What this trial is testing

Institutional Registry of Rare Diseases

Who this might be right for
Rare DiseasesAmyloidosisSarcoidosis+23 more
Hospital Italiano de Buenos Aires 380
Not applicableStudy completedNCT04844697
What this trial is testing

Resilience and Coping in a Rare Skeletal Disease Population to Face Coronavirus (COVID-19) Outbreak Distress: a Longitudinal Study

Who this might be right for
Multiple OsteochondromaOsteogenesis ImperfectaOllier Disease+1 more
Istituto Ortopedico Rizzoli 15
Testing effectiveness (Phase 2)Ended earlyNCT04171700
What this trial is testing

Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

Who this might be right for
Solid Tumor
pharmaand GmbH 83
Not applicableLooking for participantsNCT07524114
What this trial is testing

Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)

Who this might be right for
Breast CancerLung CancerMelanoma+7 more
University Health Network, Toronto 7,000